Halozyme (HALO) Q2 2026 Earnings Call Transcript

Halozyme reported Q2 2026 total revenue of $481.0M (+48% YoY) driven by record royalty revenue of $307.7M (+50% YoY). The company raised FY2026 guidance to $1.835B–$1.91B total revenue and $1.22B–$1.245B royalty revenue (+41%–43% YoY), alongside adjusted EBITDA of $328.8M (margin >65%) and non-GAAP EPS guidance of $8.65–$9.00. Halozyme also returned capital via $332.8M of share repurchases (4.8M shares at $69.30 average) and highlighted multiple growth catalysts including priority FDA review for Rybrevant Faspro in head and neck cancer and continued subcutaneous ramp (e.g., Ocrevus Zunovo patients 44,000 vs 17,500 at end-2025). Offsetting risk includes ongoing patent litigation with Merck, with management planning appeals of initial U.S. patent office decisions.

Analysis

HALO is becoming a cash-flow compounding story, not a single-asset royalty story. The market implication is that each additional subcutaneous launch lowers perceived duration risk, which can support a higher multiple even if near-term EPS beats are already visible. The underappreciated second-order effect is that the platform’s expanding use cases in ADCs and nucleic acids increases the addressable partner universe, so future growth is less tied to any one franchise and more to deal cadence.

For partners like JNJ, RHHBY, BMY and ARGX, the main economic value is franchise life extension: subcutaneous conversion expands patient access, shifts administration toward more convenient sites, and can slow IV erosion. The losers are the operationally exposed pieces of the care pathway — infusion-center utilization, hospital outpatient economics, and any IV-only competitors that rely on friction as a moat. That said, the revenue sensitivity inside large pharma is small; HALO captures the cleaner leverage.

The key risk is the litigation calendar, not the quarterly guide. A favorable 1-3 month path on PTAB/PGR and European injunctions would strengthen the durability narrative; a legal setback would hit the multiple faster than it hits near-term revenue. Contrarian view: the stock may already discount a lot of the 2026-28 story, while 2029+ depends on a long chain of launches and partner nominations. Falsifiers are simple: royalty growth missing sequentially, RYBREVANT/OCREVUS adoption slowing, or a Merck legal decision that undermines exclusivity economics.

Key Decisions for Investors

• Add to HALO on post-earnings consolidation rather than chasing strength; thesis is multi-year royalty compounding with buybacks, but only if 2H 2026 royalties keep sequentially rising.
• Use a 6-12 month HALO call-spread structure to express upside from litigation resolution and new-launch cadence while limiting premium at risk.
• Treat JNJ, RHHBY and GSK as indirect beneficiaries, not core longs; the platform upside is real but too small to move consolidated earnings meaningfully at their scale.
• Set a hard review trigger on HALO if royalty revenue or 2026 guidance is revised down, or if the Merck/PGR process turns materially against Halozyme.